NasdaqGM - Nasdaq Real Time Price USD
Inventiva S.A. (IVA)
3.7606
-0.0694
(-1.81%)
As of 11:49:59 AM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
9,198
9,198
17,477
12,179
4,194
Operating Expense
103,187
103,187
120,142
69,036
55,368
Operating Income
-93,989
-93,989
-102,665
-56,857
-51,174
Net Non Operating Interest Income Expense
-11,069
-11,069
-4,233
-364
-86
Other Income Expense
-78,843
-78,843
-2,920
2,927
1,985
Pretax Income
-183,901
-183,901
-109,818
-54,294
-49,275
Tax Provision
313
313
607
-20
364
Net Income Common Stockholders
-184,212
-184,212
-110,426
-54,274
-49,635
Diluted NI Available to Com Stockholders
-184,212
-184,212
-110,426
-54,274
-49,635
Basic EPS
-3.08
--
-2.43
-1.31
-1.27
Diluted EPS
-3.08
--
-2.43
-1.31
-1.27
Basic Average Shares
59,778.7010
--
45,351.7990
41,449.7320
39,168.1520
Diluted Average Shares
59,778.7010
--
45,351.7990
41,449.7320
39,168.1520
Total Operating Income as Reported
-97,558
-97,558
-102,709
-57,110
-52,114
Total Expenses
103,187
103,187
120,142
69,036
55,368
Net Income from Continuing & Discontinued Operation
-184,212
-184,212
-110,426
-54,274
-49,635
Normalized Income
-125,314.5000
-125,314.5000
-109,747.2500
-57,199.2438
-51,093.9750
Interest Income
1,143
1,143
991
390
57
Interest Expense
12,178
12,178
5,178
707
138
Net Interest Income
-11,069
-11,069
-4,233
-364
-86
EBIT
-171,723
-171,723
-104,640
-53,587
-49,137
EBITDA
-166,525
-166,525
-102,041
-51,889
-48,961
Reconciled Depreciation
5,198
5,198
2,599
1,698
-1,288
Net Income from Continuing Operation Net Minority Interest
-184,212
-184,212
-110,426
-54,274
-49,635
Total Unusual Items Excluding Goodwill
-78,530
-78,530
-905
2,927
1,985
Total Unusual Items
-78,530
-78,530
-905
2,927
1,985
Normalized EBITDA
-87,995
-87,995
-101,136
-54,816
-50,946
Tax Rate for Calcs
0.0003
0.0003
0.0003
0
0.0003
Tax Effect of Unusual Items
-19,632.5000
-19,632.5000
-226.2500
1.7562
526.0250
12/31/2021 - 7/10/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ELTX Elicio Therapeutics, Inc.
5.16
-1.15%
ADAG Adagene Inc.
1.5094
+5.55%
ABVX ABIVAX Société Anonyme
7.13
+5.40%
BIOR Biora Therapeutics, Inc.
0.2200
0.00%
AMPE Ampio Pharmaceuticals, Inc.
0.0217
-0.23%
NTHI NeOnc Technologies Holdings, Inc. Common Stock
5.70
-3.15%
IMCR Immunocore Holdings plc
29.88
+0.27%
NXOA.BE Nicox SA
0.2260
0.00%
BT3.BE Lineage Cell Therapeutics Inc
0.4020
+8.06%
HQ1.MU Oruka Therapeutics Inc. R
9.15
+0.55%